Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized - Scorecard - MDSpire

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

  • By

  • Sumit Sharma

  • Phoebe Lin

  • Allen Hu

  • Eric B. Suhler

  • Meike Pauly-Evers

  • William Holmes

  • Zeinab Barekati

  • Daniela Willen

  • Lachlan Macgregor

  • Laura Steeples

  • Zdenka Haskova

  • Derrick Feenstra

  • David Silverman

  • Benedicte Passemard

  • Sascha Fauser

  • Marina Mesquida

  • May 1, 2026

  • 0 min

Share

Clinical Scorecard: Inhibition of Interleukin 6 Using Vamikibart for Treating Uveitic Macular Edema: Results from the Phase 1 DOVETAIL Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingMulticenter, open-label clinical trial conducted at 18 sites.

Key Highlights

  • highlight_5

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor intraocular pressure (IOP) and visual acuity at baseline, 4 weeks, and every 8 weeks thereafter.

      Risks

        Patient & Prescribing Data

        Adults with UME secondary to noninfectious uveitis.

        Vamikibart shows promise in reducing UME and improving visual outcomes.

        Clinical Best Practices

        • best_practice_3

        Related Resources & Content

        Original Source(s)

        Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

        • by Sumit Sharma, Phoebe Lin, Allen Hu, Eric B. Suhler, Meike Pauly-Evers, William Holmes, Zeinab Barekati, Daniela Willen, Lachlan Macgregor, Laura Steeples, Zdenka Haskova, Derrick Feenstra, David Silverman, Benedicte Passemard, Sascha Fauser, Marina Mesquida

        • May 1, 2026

        Related Content

        New Tools for Imaging Retinal Inflammation

        At ARVO 2026, Ethan A. Rossi, PhD, presented data on multimodal AOSLO imaging of immune cells in the living eye.

        Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis

        Expanding the Role of Suprachoroidal Injections

        Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.